A comparative study on efficacy and safety of pioglitazone as add on therapy with standard therapy in patients with depression - A randomized open labelled prospective study.

This study aimed to assess the safety and efficacy of Pioglitazone in management of depression as an add on therapy to standard therapy in comparison with standard therapy alone. This can pave the way for new promising drug in treating depression with minimal side effects. Patients with depression fulfilling the Inclusion criteria will be included in the study. On enrollment all participants will be assessed clinically by Hamilton depression rating scale and patients with mild to moderate depression of score 10-17 will be included. Baseline investigations including CBC, RFT, LFT, FBS, PPBS, Lipid profile done before start of the study. Participants will be randomized into two groups. Participants in control group will take standard therapy T.Citalopram 10 mg OD. Participants in study group will take pioglitazone as an add on therapy to standard therapy for 12 weeks. Participants will be assessed clinically using HAM-D score after 12 weeks. All ADRs will be noted, analyzed and reported to Regional Pharmacovigilance centre using the CDSCO ADR reporting form.